Literature DB >> 19723918

Germ-line mutations in mismatch repair genes associated with prostate cancer.

Eli Marie Grindedal1, Pål Møller, Ros Eeles, Astrid Tenden Stormorken, Inger Marie Bowitz-Lothe, Stefan Magnus Landrø, Neal Clark, Rune Kvåle, Susan Shanley, Lovise Maehle.   

Abstract

Genetic predisposition to prostate cancer includes multiple common variants with a low penetrance (single nucleotide polymorphisms) and rare variants with higher penetrance. The mismatch repair (MMR) genes MLH1, MSH2, MSH6, and PMS2 are associated with Lynch syndrome where colon and endometrial cancers are the predominant phenotypes. The purpose of our study was to investigate whether germ-line mutations in these genes may be associated with prostate cancer. One hundred and six male carriers or obligate carriers of MMR mutations were identified. Nine had contracted prostate cancer. Immunohistochemical analysis was done on tumor tissue from eight of the nine tumors. Observed incidence, cumulative risk at 60 and 70 years of age, age of onset, and Gleason score were compared with expected as assessed from population-based series. Absence of gene product from the mutated MMR gene was found in seven of eight tumors. Expected number of prostate cancers was 1.52 compared with 9 observed (P < 0.01). Mean age of onset of prostate cancer was 60.4 years compared with 66.6 expected (P = 0.006); the number of men with a Gleason score between 8 and 10 was significantly higher than expected (P < 0.00001). Kaplan-Meier analysis suggested that cumulative risk by 70 years in MMR mutation carriers may be 30% (SE, 0.088) compared with 8.0% in the general population. This is similar to the high risk associated with BRCA2 mutations. To our knowledge, this study is the first to indicate that the MMR genes may be among the rare genetic variants that confer a high risk of prostate cancer when mutated.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19723918     DOI: 10.1158/1055-9965.EPI-09-0058

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  51 in total

1.  The revised Bethesda guidelines: extent of utilization in a university hospital medical center with a cancer genetics program.

Authors:  Aparna Mukherjee; Thomas J McGarrity; Francesca Ruggiero; Walter Koltun; Kevin McKenna; Lisa Poritz; Maria J Baker
Journal:  Hered Cancer Clin Pract       Date:  2010-11-22       Impact factor: 2.857

Review 2.  [Familial prostate cancer and genetic predisposition].

Authors:  V H Meissner; M Jahnen; K Herkommer
Journal:  Urologe A       Date:  2021-03-15       Impact factor: 0.639

Review 3.  Clinical implications of mismatch repair deficiency in prostate cancer.

Authors:  Ramy Sedhom; Emmanuel S Antonarakis
Journal:  Future Oncol       Date:  2019-06-25       Impact factor: 3.404

4.  Hereditary prostate cancer as a feature of Lynch syndrome.

Authors:  Christina M Bauer; Anna M Ray; Bronwen A Halstead-Nussloch; Robert G Dekker; Victoria M Raymond; Stephen B Gruber; Kathleen A Cooney
Journal:  Fam Cancer       Date:  2011-03       Impact factor: 2.375

5.  Is prostate cancer a Lynch syndrome cancer?

Authors:  Aung Ko Win
Journal:  Asian J Androl       Date:  2013-07-01       Impact factor: 3.285

Review 6.  ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes.

Authors:  Sapna Syngal; Randall E Brand; James M Church; Francis M Giardiello; Heather L Hampel; Randall W Burt
Journal:  Am J Gastroenterol       Date:  2015-02-03       Impact factor: 10.864

7.  Overexpression of RAD51 occurs in aggressive prostatic cancer.

Authors:  Anita Mitra; Charles Jameson; Yolanda Barbachano; Lydia Sanchez; Zsofia Kote-Jarai; Susan Peock; Nayanta Sodha; Elizabeth Bancroft; Anne Fletcher; Colin Cooper; Douglas Easton; Rosalind Eeles; Christopher S Foster
Journal:  Histopathology       Date:  2009-12       Impact factor: 5.087

8.  Cancer risks for MLH1 and MSH2 mutation carriers.

Authors:  James G Dowty; Aung K Win; Daniel D Buchanan; Noralane M Lindor; Finlay A Macrae; Mark Clendenning; Yoland C Antill; Stephen N Thibodeau; Graham Casey; Steve Gallinger; Loic Le Marchand; Polly A Newcomb; Robert W Haile; Graeme P Young; Paul A James; Graham G Giles; Shanaka R Gunawardena; Barbara A Leggett; Michael Gattas; Alex Boussioutas; Dennis J Ahnen; John A Baron; Susan Parry; Jack Goldblatt; Joanne P Young; John L Hopper; Mark A Jenkins
Journal:  Hum Mutat       Date:  2013-03       Impact factor: 4.878

9.  Elevated risk of prostate cancer among men with Lynch syndrome.

Authors:  Victoria M Raymond; Bhramar Mukherjee; Fei Wang; Shu-Chen Huang; Elena M Stoffel; Fay Kastrinos; Sapna Syngal; Kathleen A Cooney; Stephen B Gruber
Journal:  J Clin Oncol       Date:  2013-03-25       Impact factor: 44.544

10.  The role of germline mutations in the BRCA1/2 and mismatch repair genes in men ascertained for early-onset and/or familial prostate cancer.

Authors:  Sofia Maia; Marta Cardoso; Paula Paulo; Manuela Pinheiro; Pedro Pinto; Catarina Santos; Carla Pinto; Ana Peixoto; Rui Henrique; Manuel R Teixeira
Journal:  Fam Cancer       Date:  2016-01       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.